Comprehensive Hybrid Cardiac Rehabilitation Trial on Heart Failure (COCREATIONHF)

November 27, 2024 updated by: Pamela Serón, Universidad de La Frontera

Comprehensive Hybrid Cardiac Rehabilitation Trial to Assess Impact on Heart Failure Patients

CO-CREATION-HF aims to evaluate the effectiveness of a comprehensive and hybrid cardiac rehabilitation model compared to supervised exercise alone.

Study Overview

Detailed Description

Comprehensive, hybrid cardiac rehabilitation (CR) models have been scantly investigated in heart failure (HF) populations, particularly in low-resource settings.

A 2 parallel-arm, multi-center randomized clinical superiority trial will be conducted with blinded outcome assessment. 152 HF patients (NYHA class II or III) will be recruited consecutively, and randomly assigned. The experimental intervention will include evaluation, medical and nurse management, aerobic interval training, resistance exercise, psychosocial support, and education. These will initially be delivered in a center, transitioning to home in 4 stages. Participants in the control arm will receive face-to-face continuous aerobic exercise sessions and resistance exercises. The main outcomes are cardiorespiratory fitness, functional capacity, and quality of life. These will be measured at baseline, end of intervention, and 12-month follow-up.

The pragmatic, comprehensive hybrid CR model could be implemented more broadly if superiority is demonstrated.

Study Type

Interventional

Enrollment (Estimated)

152

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Santiago, Chile
        • Recruiting
        • Hospital Clínico Universidad de Chile
        • Contact:
          • Karen Rouliez
      • Santiago, Chile
        • Recruiting
        • Complejo Hospitalario San José
        • Contact:
          • Manuel Galvez
      • Santiago, Chile
        • Recruiting
        • Hospital San Borja Arriarán
        • Contact:
          • Gonzalo Latin
      • Temuco, Chile
        • Recruiting
        • Universidad de La Frontera
        • Contact:
          • Francisca Contreras

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adult patients with HF of New York Heart Association functional class II or III.
  • Meets HF diagnostic criteria of Guidelines
  • On optimal tolerated medical therapy.
  • Deemed by the treating physician as stable for at least 1 month.
  • Able to attend the health center three times a week for the first month, and twice a week for the 2nd and 3rd months
  • Owns a mobile phone
  • Patient consents to participate in the study by signing an informed consent form.

Exclusion Criteria:

  • Chronic kidney disease with glomerular filtration rate < 20 mL/min.
  • Decompensated thyroid disease.
  • End-stage liver failure or Child-Pugh C.
  • Cardiac device or cardiac surgery in the previous month or planned in the next 3 months.
  • Patients with dyspnea predominantly of non-cardiac cause (e.g. COPD).
  • Atrial fibrillation with a heart rate greater than 90 beats per minute at rest.
  • Active neoplasm with life expectancy <2 years.
  • Inclusion in another interventional study.
  • Explicit contraindications to performing exercise.
  • Comorbidities that preclude the patient from engaging in a CR program.
  • Musculoskeletal or neurological disease that precludes the patient from performing exercise.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Comprehensive Hybrid Cardiac Rehabilitation
The 24-week Cardiac Rehabilitation intervention will include evaluation, medical and nurse management, aerobic interval training, resistance exercise, psychosocial support, and education. These will initially be delivered in a health center, transitioning to home in 4 stages.

Initial Assessment includes all those necessary to prescribe exercise training, as well as dietary and adherence promotion interventions.

  • Functional capacity with 6MWT
  • Assessment of skeletal muscle strength, flexibility, and balance.
  • Assessment of function
  • Assessment of dietary habits
  • Assessment of self-efficacy and barriers to CR adherence.
  • Screening for depression.
Evaluations during the course of the program will be carried out to inform the progression through the CR stages, the intensity of training and education needs.

High-intensity interval training prescribed by physical therapist:

  • According to an adapted Wisloff protocol.
  • Borg scale to monitor intensity.
  • Training 3 times per week.

Based on social-cognitive theory, with self-efficacy as a focus:

  • Face-to-face sessions in the first stage of the program: Education, self-monitoring and motivational interview.
  • Face-to-face session in the second stage of the program: promoting behavior changes by self-control and self-monitoring
  • Regular communication with patients will be supported by the use of mobile devices during the third and fourth stages of program.
A dietary plan supported by a nutritionist will be made together with the patient.

Resistance exercises:

  • With TheraBand.
  • Intensity according to the perceived exertion scale
  • Twice a week.
Active Comparator: Exercise and center-based Cardiac Rehabilitation
Cardiac rehabilitation with face-to-face continuous aerobic exercise sessions and resistance exercises.

Resistance exercises:

  • With TheraBand.
  • Intensity according to the perceived exertion scale
  • Twice a week.

Moderate-intensity continuous exercise prescribed by physical therapist :

  • The intensity will be moderate, as tolerated
  • Borg scale to monitor intensity.
  • Frequency of training of 1 to 3 times per week, until completed 20 sessions in 10-12 weeks.

Includes all those necessary to plan exercise training, as usual:

  • Functional capacity with 6MWT.
  • Assessment of skeletal muscle strength.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiorespiratory fitness
Time Frame: Baseline, 6 months and 12 months.
Will be assessed during a symptom-limited cardiopulmonary exercise test using an individualized gradual incremental ramp test designed to obtain oxygen consumption (VO2max).
Baseline, 6 months and 12 months.
Functional capacity
Time Frame: Baseline, 6 months and 12 months.
Will be assessed by the six-minute walk test (6MWT)
Baseline, 6 months and 12 months.
Health Related Quality of Life
Time Frame: Baseline, 6 months and 12 months.
Will be evaluated with the Minnesota Living with Heart Failure Questionnaire (MLHFQ). This questionnaire has 21 questions, which are answered on a scale of 1 to 5. The score of the questionnaire is obtained by the sum of the answers to the 21 questions, the higher the score, the worse the quality of life.
Baseline, 6 months and 12 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Program adherence and completion
Time Frame: 6 months
Program adherence is defined as the percentage of total prescribed sessions completed. For home-based activities, the percentage of activities carried out at home of the prescribed ones will be computed.
6 months
Cost
Time Frame: 6 months
Will be assessed through micro-costing from the health care system perspective. Also out-of-pocket spending by patients will be costed
6 months
Concentration of Pro-B-type Natriuretic Peptide
Time Frame: Baseline, 6 months and 12 months.
Biomarker with prognostic utility. When it is higher than 1000 pg/mL, there is a higher probability of having events such as hospitalizations.
Baseline, 6 months and 12 months.
Functioning
Time Frame: Baseline, 6 months and 12 months.
Defined as the ability to perform basic, instrumental and advanced activities of daily living. It will be measured with the Activities of Daily Living Questionnaire - Technology (ADLQ-T). This questionnaire evaluates 7 areas: self-care (6 items), home care and management (6 items), work and recreation (4 items), shopping and money (3 items), travel (3), communication (5 items) and technology (5 items). Each item has a score, where 0 is no problem for the activity up to 3 indicating that he/she cannot perform the activity. The functional deficit is calculated for each area and for the overall questionnaire with the sum of all scores, divided by 3 and then multiplied by the total number of items answered. A higher score indicates greater impairment of ADLs.
Baseline, 6 months and 12 months.
Mortality and Hospital admission
Time Frame: 12 months
Will be measured as a composite outcome. It will be measured as a composite outcome. An adjudicating committee will confirm the events that will be expressed as the number of participants hospitalized or dead and their respective causes. All-cause and HF-specific mortality and hospitalization will be differentiated.
12 months
Upper-body muscle strength
Time Frame: Baseline, 6 months and 12 months.
Will be assessed through grip strength performed with a Jamar® Plus+ electronic handheld dynamometer. the result shall be expressed in kilograms.
Baseline, 6 months and 12 months.
Lower-body muscle strength
Time Frame: Baseline, 6 months and 12 months.
Will be assessed through the chair stand test, with the participant in a seated position in a chair. From this position, they will be directed to rise fully and return to the starting position as many times as possible over 30 seconds. The number of repetitions achieved will be recorded
Baseline, 6 months and 12 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Pamela Seron, PhD, Universidad de La Frontera

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2024

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

March 1, 2027

Study Registration Dates

First Submitted

March 4, 2024

First Submitted That Met QC Criteria

March 8, 2024

First Posted (Actual)

March 15, 2024

Study Record Updates

Last Update Posted (Actual)

December 3, 2024

Last Update Submitted That Met QC Criteria

November 27, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Fondecyt 1230787

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual participant data that underlie the results reported in the main results article, after deidentification (text, tables, figures, and appendices).

IPD Sharing Time Frame

Beginning 6 months following main results article publication.

IPD Sharing Access Criteria

Investigators whose proposed use of the data has been approved by an independent review committee.

For individual participant data meta-analysis. Proposals should be directed to Principal Investigator. To gain access, data requestors will need to sign a data access agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure NYHA Class II

Clinical Trials on Comprehensive Initial Assessment

Subscribe